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PH domain Leucine-rich repeat protein phosphatase (PHLPP) directly dephosphorylates and inacti-
vates Akt and protein kinase C, poising it as a prime target for pharmacological intervention of two
major survival pathways. Here we report on the discovery of small molecule inhibitors of the
phosphatase activity of PHLPP, a member of the PP2C family of phosphatases for which there are
nogeneralpharmacologicalinhibitors.First,theDiversitySetoftheNCIwasscreened forinhibitionof
the purified phosphatase domain of PHLPP2 in vitro. Second, selected libraries from the open NCI
database were docked into a virtual model of the phosphatase domain of PHLPP2, previously trained
withourexperimental dataset,unveilingadditional inhibitors.Biochemical andcellular assays resulted
in the identification of two structurally diverse compounds that selectively inhibit PHLPP in vitro, increase
Akt signaling in cells, and prevent apoptosis. Thus, chemical and virtual screening has resulted in the
identification of small molecules that promote Akt signaling by inhibiting its negative regulator PHLPP.
Transient phosphorylation of proteins is a fundamental
mechanism by which cells integrate and transduce signals.
Kinases and phosphatases act in dynamic opposition to con-
trol the extent, duration, and intensity of signaling and to
maintain cellular homeostasis. Dysregulation of the precisely
tuned balance between phosphorylation and dephosphoryla-
tion results in pathophysiological states.
The phosphatidylinositol-3 kinase (PI3K
a)-Akt pathway is
one of the major phosphorylation cascades that control cell
fate.
1 Stimulation by growth factors, such as EGF or insulin,
results in phosphorylation of receptor tyrosine kinases and
recruitment of effector proteins, notably PI3K, to the recep-
tors. PI3K phosphorylates the lipid phosphatidylinositol-4,5-
bisphosphate (PIP2) to yield phosphatidylinositol-3,4,5-tri-
sphosphate(PIP3).PIP3recruitsAkttotheplasmamembrane
where the protein is phosphorylated by its upstream kinase
phosphoinositide-dependent kinase-1 (PDK-1) at the activation
loop(Thr308 inAkt1).A subsequent phosphorylation occurs
at the hydrophobic motif (Ser473 in Akt1) by a mechanism
thatdependsontheTORC2complex.
2Oncephosphorylated,
Akt is released from the membrane and phosphorylates
diverse substrates throughout the cell, thus inducing a wide
range of physiological effects, notably cell growth, prolifera-
tion, and survival. In addition, Akt is a master regulator of
glucose metabolism, playing a key role in mediating the
biologicaleffectsof insulin.
3TheactivationofAktisopposed
by (1) lipidphosphatasesthat dephosphorylate,andthus remove,
the lipidsecondmessenger, and (2) protein phosphatases that
dephosphorylate, and thus inactivate, Akt. Specifically,
PTEN dephosphorylates PIP3
4 to terminate the activation of
Akt.ActivatedAktisdephosphorylatedattheactivationloop
byokadaicacidsensitivephosphatasessuchasPP2A
5,6andat
the hydrophobic motif by the recently discovered PHdomain
leucine-richrepeatproteinphosphatase(PHLPP),
7,8resulting
in inhibition of activity and promotion of apoptosis.
PHLPP was initially discovered as the phosphatase that
dephosphorylates and inactivates Akt in cells, but it also
dephosphorylates and regulates the levels of protein kinase
C (PKC) isozymes,
9 another important class of kinases that
control cell growth and survival. PHLPP is a family of three
isoforms: the alternatively spliced PHLPP1R and PHLPP1β,
andPHLPP2.
10Thephosphatasedomainsofthethreeenzymes
arehighlysimilar,with58%aminoacididentity.Theybelong
tothe PP2Cfamilyofphosphatases, which, inturn, belongto
the larger PPM (protein phosphatase magnesium/manganese
dependent) family of serine/threonine protein phosphatases,
which require Mn
2þ or Mg
2þ for their activity. The primary
known function of the PP2C family is todown-regulate stress
responses in eukaryotes.
11,12 PP2C phosphatases differ from
thoseinthePPPfamily(whichalsorequiremetalliccationsfor
their activity) by their resistance to common serine/threonine
phosphataseinhibitors such as okadaic acid andmicrocystin.
13
In fact, there are no general inhibitors of the PP2C family
available, although cyclic peptide inhibitors for PP2Cδ
14 and
small molecule inhibitors for PP2CR, identified by virtual
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screening,
15 have been reported. Given the high therapeutic
value of inhibitors for protein kinases to target disease,
16,17
discovery of phosphatase inhibitors is likely to have a major
impact in future therapeutics.
BecausePHLPPdephosphorylatesAktandPKC,position-
ingitasasuppressoroftwomajorsurvivalpathways,PHLPP
inhibition would be particularly relevant therapeutically in
diseases where survival pathways are repressed, notably dia-
betes and heart disease. Indeed, Akt and PKC activities are
repressed in both diabetes mellitus and cardiovascular condi-
tions such as myocardial infarction and ischemia-reperfusion
(I/R) injury. In diabetes mellitus, the Akt pathway is a
therapeutic target for islet transplant and survival as well as
in the treatment of associated vascular complications.
18 Akt
activity is important for β-cell growth, survival, and insulin
production.
19,20 Studies have demonstrated that transgenic
overexpression of Akt in islet β-cells gives rise to larger islets
resulting from increases in the number and size of cells.
21,22
This hypertrophy is combined with an increase in insulin
production; mice are also resistant to streptozotocin-induced
diabetes. Conversely, overexpression of kinase-dead mutants
23
or impaired PDK-1
24 in transgenic mice leads to defective
insulin production and increased susceptibility to streptozo-
tocin. Activation of Akt by different means has been used
to improve transplantation success already.
25,26 In cardio-
vasculardiseases,activationofpro-survivalpathwaysiskeyto
protect the heart from damage because cardiovascular injuries
are often linked to myocyte cell loss through apoptosis.
27-29
AkthasanumberofpositiveeffectsonI/R-mediateddamage
ofthe heart that are mediated bydifferentsubstrates.
30,31 For
example, infarct size is reduced through inhibition of GSK3β
and this effect is reversed by the PI3K inhibitors, LY 294002,
andwortmannin.InthecaseofPKC,activationofPKCεhas
been established to mediate cardiac protection from cardiac
ischemia.
32-36Ischemicpreconditioning
36andmanypharma-
cological agents,
37,38 including insulin, adenosine A1/A2 ago-
nist, bradykinin, natriuretic peptides, or erythropoietin,
achieve their protective effect through activation of Akt and
PKC. Thus, inhibition of PHLPP, a repressor of Akt and
PKC activity, would provide a novel tool promoting the
concomitant activation of the two key survival pathways.
Here we report on the discovery of small molecule inhibi-
tors of PHLPP phosphatase activity. These molecules were
identified by medium throughput chemical screening and
virtual screening of the NCI repository. We identified mole-
cules that inactivate PHLPP at low micromolar concentra-
tions in vitro, increase basal and agonist-evoked Akt
phosphorylation in cells, and suppress apoptosis.
Results
As there is no general inhibitor of PP2C, we started our
search for inhibitory small molecules of PHLPP by screening
the First Diversity Set of the National Cancer Institute. This
set comprises 1990 compounds chosen among the 140000
compounds in the repository to encompass the largest chemi-
cal space possible. These molecules were assayed in a 96-well
format, at concentrations of 100 μM, using the isolated phos-
phatase domain of PHLPP2 purified from Escherichia coli as
the enzyme and pNPP as the substrate. Statistical analysis
revealeda zvalue
39of 0.5 andasignal-over-backgroundratio
ofalmost4,indicatingtheassaywasstatisticallyvalid(Figure1a).
Dephosphorylation of pNPP results in an increase of the
Figure 1. ScreenofNCIDiversitySet.(a)Scatterplotoftherawdatafrom25differentplatesshowingcontrol(DMSO)(graysolidcircle)and
background (absence of enzymes) values (open tilted square). The solid lines represent the mean of the control and background data and the
broken lines display 3standarddeviations (SD) from the meanof each data set. The z-factor is 0.5, and the signal-overbackground ratio is 3.8.
(b)RepresentativetimecourseforthehydrolysisofpNPPbyPHLPP2catalyticdomain.pNPP(8mM)wasincubatedin125μLassaybufferat
room temperature, without (open tilted square) or with the phosphatase domain of PHLPP2, in the presence of DMSO (gray solid circle) or
benzylcarbamic acid (NCS 24515) (solid square). The absorbance of the solution was recorded at 405 nm and the data fit by linear regression.
(c) Representative activity data from one 96-well plate. NCI plate 4238 was assayed for PHLPP2 activity as in (b). Each compound is
represented by a black bar, DMSO controls are represented by gray bars (background controls were omitted on this graph). The values
obtained for the DMSO controls were averaged and normalized to a relative activity of 1.0 (black line). Compounds that reduced PHLPP2
relative activity to lower than 0.3 (red line) were considered a hit (lane 86).Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6901
optical density of the solution, thus the slope of the change of
OD over time served as a measure of the activity of the phos-
phatase (Figure 1b). In one assay, 80 compounds can be
tested, as well as 12 controls of uninhibited activity (DMSO)
and four controls for background (absence of enzyme).
Activity in each well was measured and the value normalized
to that in the absence of inhibitor; 88 compounds were
identified that reduced activity to below 0.3 of the control
value (Figure 1c), the criterion chosen to warrant further
testing as an inhibitor. Colored compounds, which interfered
with the colorimetric assay, were further tested at concentra-
tions of either 10 or 20 μM depending on the intensity of the
color. Finally, the IC50 values of the 50 most promising com-
poundsweredetermined;theserangedfrom1to100μM,with
10% false positives for which the colorimetric change was
unrelated to phosphatase activity. Structural analysis of
inhibitory molecules led to the identification of 11 different
chemical backbones (Figure 2 and Supporting Information
Figure 1). Wethen retested other compounds oftheDiversity
Set with these backbones and uncovered 49 additional
inhibitors.
We turned to virtual screening to expand the scope of our
investigation. Docking programs have been successfully used
to identify novel inhibitory compounds of crystallographi-
cally solved signaling phosphatases,
40-42 including PP2CR.
15
We employed the GLIDE algorithm because it is well-
established in virtual drug discoverywork and hasperformed
well in comparative docking studies.
43-45
Because of the lack of crystallographic data,a structurefor
PHLPP2 based on homology modeling was created that was
capable of discerning inhibitory binding compounds from
nonbinding compounds. The first step consisted of designing
amodelthatwouldcorrelatebestwithourexperimentaldata.
TheaminoacidsequenceofthePHLPP2phosphatasedomain
was aligned with that of the phosphatase domain of PP2CR,
resulting in an alignment score of 23% (Figure 3a), and a
homology model was then produced based on the crystal
structureofPP2CR.
46Initialdockingresultsofourcontrolset
of known inhibitors using GLIDE did not correlate well with
aforementioned inhibitors of PHLPP2. Thus, we concluded
thatourhomologymodelwasnotinanoptimalconformation
or that metal ions or water molecules played a critical role in
inhibitor binding. Because many of our inhibitors contain
negatively charged moieties, the interaction between these
groups and the metal ions are predicted to contribute signifi-
cantly to the overall binding energy. The crystal structure of
PP2CR coordinates 2 Mn
2þ ions in the catalytic center. PP2C
phosphatases in mycobacteria were found to accommodate a
thirdmetalliccenterintheircatalyticcore.
47-49Previouswork
has also shown that the PP2CR active site metal ions are
coordinated by six different water molecules. Because our
structure is a homology model of the phosphatase domain of
PP2CR, it should include 1-3M n
2þ ions and coordinated
watermolecules.Wetestedthisbyplacingvaryingnumbersof
Mn
2þ ions inside the active site near residues that could
coordinate them and relaxed each structure to accommodate
the ions. This resulted in a variety of structures, which we
tested for the ability to recognize inhibitory compounds. All
structures with 1 or more Mn
2þ ions in the active site
recognized inhibitors markedly better than the structure with
no Mn
2þ ions (Figure 3c).
Next, the entire Diversity Set was docked against our
model. This served as a means to test the model for its ability
todiscriminatetrueinhibitorsfromadecoysetofligandswith
no experimental activity. The docking protocol was modified
so that only the top 4% of ligands were given final docking
Figure 2. Chemical structures of some inhibitors of PHLPP2. Different compounds that have been identified as inhibitors of PHLPP2 are
presentedalongwiththeexperimentalIC50determinedat8mMsubstrate.Thechemicalbackbonesusedtodeterminethestructuralfamiliesare
highlighted.6902 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Sierecki et al.
scores, as would be the case during virtual screening. From
these studies, we determined that the model with two Mn
2þ
ions in the active site coordinated by D806, E989, and D1024
was most capable of discriminating true binders from decoys.
In addition, this model had the highest range of G-scores for
truehits(Figure3c,model4andFigure3b).Additionofwater
molecules did not improve detection of true inhibitors,
although it is likely that they contribute to the coordination
ofionsintheactivesite.Fortynewcompoundswerefoundto
dock with G-scores better than -7 kcal/mol, in addition to
some of the previously characterized inhibitors. These new
virtual hits were tested experimentally and 14 of these new
compounds were determined tohave IC50values below 100 μM.
Rarely do docking studies serve as a means to identify false
negatives in a chemical screen but, in this case, combining
chemicaltestingandvirtualtestingpreventedusfrommissing
14 inhibitors of PHLPP. Model 4 was chosen for further
studies because of its ability to distinguish hits from decoys
and value in identifying 14 false negatives in the chemical
screen.
Armed with a substantial data set of inhibitory molecules,
we hypothesized that finding similar structures and docking
them might enlarge our pool of known binders and increase
our hit rate over random virtual screening of the NCI
repository. As previously mentioned, 11 structurally related
compound families were identified from in vitro screening;
these were used as the references for similarity searches
performed on the NCI Open Compound Library (Figure 3d).
Inaddition,sevenofthehighestaffinitycompoundswerealso
usedasreferencecompoundsforsimilaritysearches.Atotalof
43000 compounds were identified from these similarity
searches and docked to model 4. Eighty compounds among
the top ranked structurally similar compounds were tested
experimentally, at concentrations of 50 μM, using the same
protocol as described for the original screen. These 80 com-
poundswereselectedbasedongooddockingscores,structural
diversity, and availability from the NCI. Twenty-three com-
pounds reduced the relative activity of the PHLPP2 phos-
phatase domain to below 0.5 of control and were considered
hits.Ofthese,20compoundshadanIC50below100μM,with
15 of these having an IC50 value below 50 μM (Figure 4).
Thus,wediscoveredanumberofnew,experimentallyverified
low-μM inhibitors by integrating chemical data into our
virtual screening effort.
We next undertook a kinetic analysis of select compounds
to determine their mechanism of inhibition. Because the
chemical and virtual screen focused on the isolated phospha-
tasedomain,weexpectedinhibitorstobeprimarilyactive-site
directed rather than allosteric modulators. Determination of
the rate of substrate dephosphorylation in the presence of
increasing concentrations of the inhibitors revealed three
types ofinhibition: competitive, uncompetitive, and noncom-
petitive(datanotshown).WedockedpNPP(Figure5a)anda
phosphorylated decapeptide based on the hydrophobic motif
sequence of Akt (Figure 5b; HFPQF
pSYSAS) into the active
site of our best homology model, in the same manner as
described for the inhibitors, to determine which substrate
binding sites our inhibitor compounds could be blocking.
Competitive inhibitors (e.g., 7 (NCS 134149); Figure 5c,e)
werepredictedtoeffectivelyblockthebindingsiteofpNPP,as
expected for a competitive inhibitor. In contrast, uncompeti-
tiveinhibitors(e.g.,4(NCS13378);Figure5d)andmostofthe
compoundsdeterminedfromourvirtualscreen(e.g.,13(NCS
45586); Figure 5f) were predicted to bind the hydrophobic
cleft near the active site and interact with one of the Mn
2þ
ions. Noncompetitive inhibitors (e.g., 2 (NCS 47924)) tended
to dock poorly into our model, as expected if they bind sites
distal to the substrate-binding cavity. Note that pNPP is a
small molecule which, although it binds the active site and is
effectively dephosphorylated, does not recreate the complex
interactions of PHLPP with hydrophobic motifs and large
peptides. Therefore, the type of inhibition we observe toward
Figure 3. Virtual screen for inhibitors using modeled structure of PHLPP2 phosphatase domain. (a) Sequence alignment of PP2CR and
PHLPP2. Amino acids in red may be important for coordinating metal ions. * denotes a conserved residue. (b) Three-dimensional
representation of model 4 of table (c) with D806, E989, and D1024 shown coordinating 2Mn
2þ ions in the phosphatase active site. (c) Table
indicating the functional relevance of modified homology models. Model 4 was chosen for further docking because of its high docking scores
and good performance identifying true hits from the Diversity Set. The number of true hits is derived from docking 50 compounds with
experimentally derived IC50s for PHLPP2 and determining how many compounds scored better than -7. (d) Structural similarity search to
create libraries of compounds similar to known binders of PHLPP2. Selected compounds were docked with the GLIDE algorithm employing
calculations at three levels of accuracy, removing lower scoring compounds at each stage.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6903
pNPP may not necessarily hold for peptides or full-length
proteins. Importantly, we identified a number of inhibitors
predicted to dock well in the active site and with kinetic
parameters (competitive or uncompetitive inhibition) consis-
tent with such docking.
We next tested whether the six most-promising com-
pounds: (1) inhibited PHLPP in cells, and (2) were selective
for PHLPP compared with other phosphatases in vitro. To
investigate PHLPP inhibition in cells, HT29 cells (colon
cancer cell line) were treated for 24 h with compounds at
concentrations of either 100 or 250 μM, and the effect on Akt
was assessed by examining the phosphorylation state of Akt
on Ser 473 (the direct target of PHLPP) and, in addition, the
phosphorylation state of two downstream targets of Akt,
FoxO1, and GSK3 (Figure 6a,b). We chose to use HT29 cells
for this study because the protein levels of PHLPP are not
regulated by the level of Akt activity, as occurs in other cell
lines via a recently described negative feedback loop.
50,51 All
compounds except 2 (Figures 6a,b, lane 7) caused an increase
in the phosphorylation of Akt on Ser 473, with maximal
increases of 4-fold caused by several of the compounds (see
Figure 6b). Of these, four compounds (1 (NCS 117079), 24
(NCS11404),4,and13)causedcorrespondingincreasesinthe
phosphorylation of the downstream substrates GSK3 R/β on
Ser21/9 and FoxO1/3R on Thr 24/32. We have previously
shownthatknockdownof eitherPHLPP1or PHLPP2increases
the phosphorylation of FoxO1 on Thr 24 and GSK3β on
Ser9.
8Somecompoundsselectivelyincreasedthephosphoryl-
ation of the downstream substrates but not Akt (e.g., lane 7),
and others caused an increase in the phosphorylation of Akt
but only one of the downstream substrates (e.g., lane 8).
Compound 4 (lane 5) induced cells to detach from culture
dishes, reflecting toxicity of the compound.
In parallel with the cell study above, we tested the in vitro
selectivity of the inhibitors by measuring their effect on the
activity of the phosphatase domain of related and unrelated
phosphatases.Figure6cshowstheeffectoftheseinhibitorson
the in vitro activity of the phosphatase domain of PHLPP2
(black bars),PP1 (dark-graybars),PP2B (white),and PP2CR
(light-gray bars). A number of compounds proved to be
selective for the PP2C domain of PHLPP2 over the other
phosphatases tested, including the related family member,
PP2CR.Weshouldpointoutthat,amongthe54inhibitorsfor
PHLPP2 tested against PHLPP1, none was specific; at best,
IC50s were 5-fold different (data not shown), not unexpected
given the high sequence homology of the phosphatase
domains of the two isoforms. The most selective molecule for
the PHLPP phosphatase domain was compound 1:ac o n c e n -
tration of 10 μM resulted in 80% inhibition of PHLPP2, with
no significant effect on the activity of the other phosphatases.
A 10-fold higher concentration resulted in approximately
50% inhibition of PP1 and PP2CR, indicating thatthe selecti-
vityforPHLPPwasoveranorderofmagnitude.Importantly,
compound 1 increased Akt phosphorylation and activity in
cells. Compound 13 was also noteworthy: it selectively in-
hibited PHLPP2 compared to the other phosphatases tested
(Figure6c,lane6)andwasoneofthecompoundsthatinduced
a robust increase in the activity of Akt (Figure 6b, lane 6).
Thus, compounds 1 and 13 were chosen for further studies.
Their IC50 values for inhibition of pNPP dephosphorylation
were 5.45 ( 0.05 μMa n d3 . 7 0( 0.06 μM, respectively
(Figure 6d,e).
Figure 4. PHLPP2 inhibitorsfrom thevirtualscreening. (a)Tableofexperimentally confirmed inhibitors ofPHLPP2 andtheirestimated free
energyofbinding(kcal/mol)aswellasIC50.(b)Two-Dimensionalrepresentationsofselectedcompoundsfromthedockingstudywhichinhibit
PHLPP2 from the docking study.6904 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Sierecki et al.
The inhibitory potency of compounds 1
52 and 13 on
PHLPP activity in cells was determined next. To discriminate
between specific effectsof the compounds on PHLPPactivity
vs nonspecific effects, we took advantage of the finding that
PHLPP specifically and directly dephosphorylates Ser473 of
AktanddoesnotdephosphorylateThr308.
7Fortheseexperi-
ments, we examined the effect of the compounds on Akt
phosphorylation in serum-starved cells in case PHLPP sup-
pression is more dominant when Akt phosphorylation is
maximally suppressed.
COS 7 cells, serum-starved for 24 h, were treated with
increasing concentrations of the inhibitors for 35 min and the
phosphorylationofAktonSer473andThr308wasdetermined;
we also examined the activity of Akt by probing for the
phosphorylationof downstreamsubstrates withantibodiesthat
recognize phosphorylatedAkt substrates (Figure 7a-d). Treat-
ment of cells with compound 1 resulted in an approximately
6-fold increase in the phosphorylation of Ser473 and a 4-fold
increase in the phosphorylation of downstream substrates, with
half-maximal increases caused by 29.1 (0.3 and 36.4 (0.3 μM
inhibitor for Ser473 and substrate phosphorylation, respec-
tively. Importantly, at the concentration of compound causing
a half-maximal increase in phosphorylation of Ser473, there
was little effect of compound 1 on the phosphorylation of
Thr308(Figure 7b,arrow).Higherconcentrationsdidcause an
increase in phosphorylation of Thr308; half-maximal increase
in Thr308 phosphorylation was observed for 132 ( 1 μM
inhibitor. Thus, the compound selectively increased Akt phos-
phorylation on Ser473 and this resulted in a commensurate
increase in the activity of Akt. A similar increase in the
phosphorylation on Ser473 and substrate phosphorylation
was observed with compound 13. Specifically, this compound
also caused an approximately 4-fold increase in the basal
phosphorylation of Akt, with half-maximal increase caused
Figure 5. ModelofactivesiteofPHLPP2dockedwithsubstrateorinhibitors.(a)pNPP,(b)aphosphopeptidebasedonthehydrophobicmotif
of Akt (HFPQFpSYSAS, where the phosphorylated Ser corresponds to Ser473); (c) compound 7, (d) compound 4, and (f) compound 13 were
docked in the PHLPP2 model 4. Ligands are represented in tube format, Mn
2þ ions are represented as yellow spheres, and surface
representation of PHLPP2 shows the electrostatic potential where blue represents positive, white neutral, and red negative electrostatic
potential.Dockedsubstratesorinhibitorsareingreen,thephosphategroupsarehighlightedinpurple.*denotesthecarbonylgroupofGly745
in all views. (e) Lineweaver-Burke analysis of inhibition mechanism of compound 7. The activity of PHLPP was measured at eight different
concentrations of pNPP in the presence of DMSO (gray solid circle), 5 μM (solid square), 10 μM (gray solid square), or 30 μM (open square)
compound 7.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6905
by 70.6 ( 0.6 μM compound. The phosphorylation of the
downstream substrates FoxO 1/3RandGSK3 βincreasedwith
comparable kinetics. For this compound, the sensitivity of
phosphorylation of Akt on Thr308 was not significantly dif-
ferent from that of Ser473 (Figure 7d, lower panel). These data
revealthatcompounds1and13selectivelyinhibittheactivityof
Figure 6. Cellular potency and specificity of PHLPP inhibitors. (a,b) Effect of different inhibitors on Akt phosphorylation. HT29 cells in
DMEM supplemented with 5% FBS were treated for 24 h with different compounds (see table). Blots were probed with antibodies specific to
phospho-Akt (S473), phospho-GSK3R/β (S21/9), phospho-FoxO1/3a (T24/32), and actin. (b) Densitometric analysis was performed on blots
from three separate experiments. The levels of phosphoproteins are normalized to actin. The phosphorylation of Akt at Ser 473 (white bars),
FoxO 1/3 (light-gray bars), and GSK 3R/β (dark-gray bars) is calculated relative to control lanes. The graph represents mean values ( SEM
from threeseparate experiments. (c)Selectivity toward otherphosphatases.pNPP (8mM)wasincubated in 125μLoftheoptimal assaybuffer
for each protein, in the presence of the PP2C domain of PHLPP2 (black bars), PP1 (dark-gray bars), PP2B (white bars), or PP2CR (light-ray
bars).Compounds(seetable)wereadded.TheactivityoftheenzymeisrelativetotheDMSOcontrol.Thegraphrepresentsmeanvalues(SEM
of at least three different experiments. * denotes that compound 13 was tested at 100 and not 250 μM (d,e) in vitro inhibition curves for
compound 1 (d) and 13 (e). The inhibitor, diluted in DMSO, was incubated in assay buffer with 8 mM pNPP in the presence of 1 μM enzyme.
Activity was calculated relative to DMSO alone. The mean activity ( SEM for five different experiments are represented (gray solid circle, 1;
gray tilted solid squares, 13) and were fit with eq 1.6906 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Sierecki et al.
PHLPP toward Akt in cells, with IC50 values of approximately
30 and 70 μM, respectively. Compound 1 has higher selectivity
toward PHLPP as assessed by the uncoupling of phosphoryla-
tion at Ser473 and Thr308. At concentrations above 100 μM,
this compound loses specificity as evidenced by the increase in
Akt phosphorylation at both Ser473 and Thr308. Compound
13 was considerably less effective at modulating Ser473 phos-
phorylation in cells grown in serum (data not shown). In
contrast, compound 1 increased Akt phosphorylation on
Ser473 by 2-fold with comparable kinetics in the presence of
serum. This acute treatment of cells with inhibitors did not
change the levels of PKC isozymes (data not shown), as
expected because PHLPP provides chronic control of PKC
levels
9 (see Discussion).
PHLPP controls the basal phosphorylation state of Akt as
well as the amplitude of the agonist-evoked increase in
phosphorylation of Akt.
8 We therefore tested the effect of
the inhibitors on agonist-evoked phosphorylation of Akt by
pretreating serum-starved COS-7cells withor without 50μM
of 1 and then stimulating with EGF (Figure 7e,f, open
symbols (DMSO) and dark symbols (inhibitor)). As in pre-
vious experiments, the basal phosphorylation at Ser473 was
significantly higher in cells treated with 1 compared with
DMSO (Figure 7e, compare lanes 1 and 7). In cells treated
with DMSO, addition of EGF caused an approximately
7-fold increase in the phosphorylation of Akt on Ser473 that
peaked after 8 min (Figure 7f, top panel). In contrast, EGF
had a smaller effect on the already elevated phosphorylation
of Akt on Ser473 in cells treated with 1 (Figure 7f, top panel).
Phosphorylation at Thr308 was slightly elevated under basal
conditions in cells treated with the inhibitor compared to
control cells (Figure 7e, lanes 1 and 7). EGF treatment
resulted in an approximately 6-fold increase in p308 phos-
phorylation for both control and treated cells, which peaked
earlier in inhibitor-treated cells (Figure 7f, middle panel).
Thus, the magnitude of the increase in p308 and p473
phosphorylation was comparable in inhibitor vs DMSO-
treated cells, but the rate of phosphorylation on p308 was
Figure 7. Effect of inhibitors on Akt-dependent signaling in cells. COS 7 cells were incubated in serum-free DMEM for 24 h and then treated
for 35 min with compound 1 (a,b) or 13 (c,d) at different concentrations. The control corresponds to 35 min of treatment with DMSO alone.
The graph represents mean values ( SEM from four separate experiments. (a,b) Blots were probed with antibodies specific to phospho-S473,
phospho-T308, an antibody specific to phosphoserine or phosphothreonine in a consensus sequence for Akt, and actin. (b) The levels of
phospho-Akt at Ser473 (open tilted square), at Thr308 (open circle) and phosphorylation of Akt substrates (gray tilted solid square) are
normalized to total actin and relative to the level of phosphorylation in the control lanes. Arrow denotes IC50 value for inhibition of Ser473
phosphorylation. (c,d)Blotswereprobedwith antibodiesspecifictophospho-S473,phospho-T308, phospho-GSK3 R/β,phospho-FoxO1/3a,
andactin.(d)Thelevelsofphospho-AktatSer473(opentiltedsquare),atThr308(opencircle),andphosphorylationofAktsubstrates(GSK3:
open square; FoxO, gray solid downward-pointing triangle) were normalized to total actin and relative to the level of phosphorylation in the
control lane. Arrow denotes IC50 value for inhibition of Ser473 phosphorylation. (e,f) Effect of compound 1 on the agonist-evoked
phosphorylation of Akt. COS 7 cells were incubated in serum-free DMEM for 24 h. The cells were pretreated with DMSO (dark symbols)
or compound 1 (50 μM) (open symbols) for 35 min. EGF (1 mg3mL
-1) was then added at various time. Blots were probed with the specified
antibodies. (d) The levels of phospho-Akt and phospho-ERK were normalized to actin. The phosphorylation of Akt at S473 (solid tilted
square, DMSO; open tilted square, 1), of Akt at T308 (solid circle, DMSO; open circle, 1) and ERK (solid upward-pointing triangle, DMSO;
open upward-pointing triangle, 1) are relative to the levels of phosphoprotein in unstimulated cells treated with DMSO (lane 1). The graphs
represent mean values ( SEM from five separate experiments.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6907
significantly faster in inhibitor-treated cells and, most strikingly,
the basal phosphorylation on Ser473 was highly elevated in
inhibitor-treated cells. To discern whether this coupled phos-
phorylation of p473 and p308 resulted from off-target effects
of the inhibitor or reflected the stabilization of phosphate on
T308whenSer473isphosphorylated,
8weexaminedtheEGF-
dependent phosphorylation of ERK 1/2: the kinetics and
magnitudeoftheEGF-stimulated increaseinERKphos-
phorylation were the same for control cells and cells treated
with the inhibitor (Figure 7f, bottom panel).
BecauseamajorfunctionofactivatedAktistopromotecell
survival, a function enhanced by loss of PHLPP,
7 we asked
whethertreatmentofcellswithcompounds1or13suppressed
etoposide-inducedapoptosis.COS7cellswerepretreatedwith
DMSO, 1,o r13 (at 50 μM) for 30 min, then treated with
DMSO or etoposide for 24 h (Figure 8). Etoposide treatment
of control cells resulted in a (3.4 ( 0.4)-fold increase in
apoptotic cells, as assessed by Trypan Blue exclusion. Pre-
treatment of cells with compound 1 reduced the magnitudeof
this increase by approximately 30%, to only (2.6 ( 0.3)-fold,
and pretreatmentwithcompound13 essentially abolishedthe
etoposide-induced increase in apoptotic cells. Note that the
basal level of apoptotic cells was comparable in control cells
andcellstreatedwithcompound13(approximately3.4%)but
elevated in cells treated with compound 1 (approximately
12%). These data reveal that the PHLPP inhibitors protect
cells against etoposide-induced apoptosis.
Discussion
By combining experimental and computational methods,
wehaveidentifiedthefirstsetofinhibitorsofthephosphatase
PHLPP, a member of the PP2C family of phosphatases that
has hitherto remained refractory to identification of general
inhibitors. Specifically, we have identified small molecules
that selectively inhibit PHLPP and show that treatment of
cellswiththeseinhibitorsincreasesboththebasalandagonist-
evokedphosphorylationofAkt.Mostrelevantfortherapeutic
goals, these inhibitors selectively suppress cellular apoptosis.
We have specifically identified two molecules, with chemi-
cally distinct backbones that display selectivity for PHLPP
both in vitro and in cells. Compound 1 (1-amino-9,10-dioxo-
4-(3-sulfamoylanilino)anthracene-2-sulfonic acid, sodium salt)
possessesananthracenecore,whereascompound13(1,3-[[4-(2,4-
diamino-5-methylphenyl)diazenylphenyl]hydrazinylidene]-
6-oxocyclohexa-1,4-diene-1-carboxylic acid) has aromatic groups
linked by two diazene bonds. They inhibit PHLPP2 activity in
vitro with IC50 values of 5.45 ( 0.05 and 3.70 ( 0.06 μM,
respectively. Kinetic analyses reveal that both molecules are
noncompetitive inhibitors with respect to pNPP. Both mole-
cules are selective for PHLPP compared to other phosphatases
tested: neither molecule affected the activity of PP2B at the
highest concentration tested (100 μM) and inhibited PP1 and
PP2CR with IC50 values of approximately 100 μM( F i g u r e6 c ) .
Bothcompound1and13showthepotentialfortherapeutic
development. Quikprop from the Schrodinger Suite was run
to estimate properties that are potentially important to com-
pound solubility, permeability, and drug development.
53 The
Lipinskirulesindicatethatapotentialdrugcompoundshould
not contain more than 5 H-bond donors, 10 H-bond accep-
tors, a LogP (predicted octanol/water partition coefficient)
greater than 5, or a molecular weight greater than 500 Da
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(Table 1). There are no Lipinski violations for 13,a n d1
contains one violation from extra H-bond acceptors. Virtual
dockingof13(Figure5f) showsmultipleinteractionsbetween
thearomaticcyclesofthecompoundsandresiduescomposing
the hydrophobic cleft as well ascoordination of one Mn
2þ by
the acid moiety. Compound 1 was discovered by chemical
screening and does not perform well in the virtual docking, so
little information can be gained this way. Note that both
compounds are a dark color and both tend to precipitate in
the cell culture medium at high concentration (>300 μM).
Cellular studies with compound 1 revealed that, at concen-
trations below 100 μM, it selectively inhibited the PHLPP-
catalyzed dephosphorylation of Akt on Ser473 with little
effect on the dephosphorylation on Thr308, a site that is not
recognizedbyPHLPP. Indeed theIC50valueforinhibition of
Ser473 dephosphorylation (29.1 ( 0.3 μM) was considerably
lower than that for Thr308 dephosphorylation (132 ( 1 μM).
At concentrations above 100 μM, the phosphorylation of
Thr308 increased. This could result from off-target effects at
higher concentrations, possibly by modulation of other phos-
phatases,orcouldreflectthestabilizationofthephosphoryla-
tion onThr308by phosphorylation onSer473.
8 Interestingly,
elevation of the phosphorylation of Ser473 alone, and not
Thr308, resulted in an accompanying increase in the phosphor-
ylationofdownstreamsubstratesofAkt,includingFoxO1/3and
GSK3 R/β. These data reveal that phosphorylation on only
Ser473 activates cellular Akt sufficiently to mediate downstream
signaling. Compound 13 was also an effective inhibitor of Akt
dephosphorylation but displayed less selectively toward inhibit-
ingthedephosphorylationofSer473comparedtoThr308.Thus,
both compounds are effective inhibitors of Akt dephosphoryla-
tion, with compound 1 displaying almost 1 order of magnitude
selectivity for Ser473 compared to Thr308.
Akt plays a key role in controlling the balance between cell
survival and cell death. Disruption of this balance results in
Figure 8. Effectofinhibitorsonetoposide-inducedcelldeath.COS
7 cells in DMEM supplemented with 0.1% FBS were treated for
30 min with DMSO, 1,o r13 at 50 μM followed by a 24 h treatment
with DMSO or etoposide. Cells were then submitted to a Trypan
Blue exclusion assay. The graph shows the etoposide-induced
increase in cell death (compared to DMSO) and represents mean
values ( SEM of three separate experiments .* corresponds to
p values <0.0005 and ** corresponds to p values e2   10
-5.
Table 1. Calculated Chemical Properties of Compounds 13 and 1
a
compd
molweight
(daltons)
donor
H-bonds
acceptor
H-bonds LogP
13 390 4 7.75 2.27
1 473 4 12 0.097
aQuikpropwasruntocalculatethechemicalpropertiesthatmakeup
the Lipinski rules.6908 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 Sierecki et al.
severe pathological states. Most notably, in heart disease and
diabetes, the balance is pushed toward cell death. Therapies
arethustargetedtowardenhancingcellsurvival.Theabilityof
our compounds to selectively activate Akt, by inhibiting its
negative regulator PHLPP, poises them as prime therapeutic
molecules for diseases in which Akt activity is repressed.
Indeed, both molecules effectively suppressed etoposide-
induced apoptosis, with compound 13 abolishing etoposide-
induced apoptosis under the conditions of our assays. The
moredramaticeffectofcompound13mayreflectitsabilityto
modulate the phosphorylation of both Ser473 and Thr308.
Thus, these molecules hold promise as the basis for novel
therapeutics for diseases in which cell survival pathways are
suppressed.
PHLPP also controls PKC isozymes: particularly in the
case of the conventional isozymes, phosphorylation of the
hydrophobic motif is constitutive and protects PKC from
degradation. Dephosphorylation at this site triggers the
down-regulation of the enzyme. Thus, PHLPP controls the
amplitudeofthePKCsignalbycontrollingthelevelsofPKC.
Genetic depletion ofPHLPPresultsin elevated levels ofPKC
because phosphate on the hydrophobic motif is favored.
However, PKC has a relatively long half-life (greater than
24h),sochronicinhibitionofPHLPPisrequiredtomodulate
PKC levels. For this reason, the acute treatment of cells
with inhibitors of PHLPP in this study did not modulate
PKC levels.
In addition to uncovering new molecules to activate Akt
signaling in cells, this work underscores both the value of
computational work in drug discovery campaigns and the
value of using chemical data to increase the efficiency of
computational work. Theefficiency of the experimental work
was largely increased by the use and refinement of a virtual
model in this drug development campaign. The primary
screen of the Diversity Set identified 50 inhibitors out of
1990 tested, a random search yielding 2.5% hits. Overall, we
identified 95inhibitorsofPHLPPin this set, representing 5%
of the tested compounds. When the same set was first sub-
mitted to a virtual screen, 14 inhibitors were found out of
36 tested, increasing the experimental hit ratio to 16%. Finally,
when the virtual screen was combined with a structural com-
ponent, the experimental hit ratio reached 25%, a 10-fold
increase,highlightingthevalueofcomputationalmethodsfor
drug discovery.
Given the lack of structural information available for
PHLPP,thisworkhadtobranchoutfromtraditionaldocking
studies. Although crystal structures are commonly preferred
for docking studies, we have demonstrated that homology
models, when carefully constructed and correlated to experi-
mental results, can provide success in the search for new
inhibitory ligands. The construction of our model included
the modeling of metal ions and water molecules in the active
site and some changes in conformations. As demonstrated by
these data, placing metal ions in the active site can be
extremely important in molecular modeling studies of this
nature.Water molecules can also playa large rolein inhibitor
binding, but it is difficult to predict how the water molecules
will be coordinated in the active site and which water mole-
cules maybedisplaced by different inhibitors without crystal-
lographic information. This may be the reason we did not
observe an improvement in performance when adding water
molecules to our homology structure. In addition to identify-
ingnewinhibitorsbyvirtualdocking,ourdockingstudiesalso
revealed the mechanism of binding of the various inhibitions
(competitive, uncompetitive, or noncompetitive), with results
validated by biochemical studies.
Compounds that inhibit PP2C phosphatases have been
fairly refractory toidentification, withfew publishedstudies.
14,15
Here,wehaveidentifiedanumberofsmallmoleculesthatnot
only inhibit this family of phosphatases but also selectively
inhibit PHLPP compared to other phosphatases, including
the highly related phosphatase PP2CR. The combination of
computational and chemical work allowed us to identify a
variety of structurally distinct inhibitors for a phosphatase
target without the need foramassive high-throughput chemi-
cal screen. It is noteworthy that these tests were performed
withouttheuseofroboticsorhighlyautomatedmethods,and
the virtual screening was performed on a common desktop
computer. Thus, collaboration between chemical and virtual
screening provides an extraordinarily effective approach to
drug discovery. Further refinement of these compounds to
tunethemtohigheraffinityandmorespecificinhibitorsoffers
great therapeutic potential. Our identification of these new
inhibitors for a PP2C family member is particularly relevant
because these compounds could be potential therapeutics
giventhestrategicpositionofPHLPPincellsurvivalpathways.
Experimental Section
The Diversity Set and compounds identified by virtual screen
were obtained from the Drug Synthesis and Chemistry Branch,
DevelopmentalTherapeuticsProgram,DivisionofCancerTreat-
ment and Diagnosis of the National Cancer Institute (http://
dtp.nci.nih.gov/branches/dscb/repo_open.html). The compounds
were used as provided in the in vitro assay. Purity of the com-
poundsusedtotreatcellswasverifiedbyLC/MSusingaThermo
LCQdeca mass spectrometer coupled with a Michrom Bio-
ResourceHPLCattheUCSDChemistryandBiochemistryMass
SpectroscopyFacility.Negativeionmodeelectrosprayionization
wasused.Puritywasfoundtobe>90%forcompounds24and4,
80% for compound 2, 60% for compound 7, and 55.5% for
compound 13. See Supporting Information for compound 1.
The following phosphatases were purchased: PP1 (New England
Biolabs),PP2B/calcineurin(Enzo).PP2CRwaspurifiedfromE.coli
as previously described.
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The following polyclonal antibodies werepurchased fromCell
Signaling: phosphospecific to phosphorylated Akt at Ser473
(S473) (no. 9271), phosphospecific to phosphorylated Akt at
Thr308 (T308) (no. 9275), phosphospecific to phosphorylated
Ser/ThrAktsubstrate(no.9611),phosphospecifictophosphory-
lated GSK 3 R/β at Ser 21 and Ser 9, respectively (S21/9) (no.
9331), phosphospecific to phosphorylated FoxO1/3a at Thr 24
and Thr 32, respectively (T24/32) (no. 9464), phosphospecific to
phosphorylated p44/42 MAPK(Erk 1/2) at Thr 202 and Tyr 204
(T202/Y204)(no.9101),antibodyagainstp44/42MAPK(Erk1/2)
(no. 9102). Monoclonal antibody against actin was purchased
from Sigma-Aldrich (no. A4700).
Experimental in Vitro Screen. In each well of a 96-well plate,
125 μL of a reaction mixture (100 mM tricine pH 7.5, 100 mM
NaCl, 4 mM DTT, 0.02 mg3mL
-1 BSA) containing 8 mM
pNPP as the substrate, 1 μM enzyme and 100 μM compound
were added. Reactions occurred at 23  C. The optical density
was monitored over time at 405 nm using an Emax Precision
microplate reader (Molecular Devices). The absorbance was
plotted against the time, and the slope was calculated. Back-
ground was averaged from four different reactions in the
absence of enzyme and subtracted. Eight different controls
(containing5μLofDMSO)wereaveragedandusedtocalculate
the relative activity.
In Vitro Inhibition Concentration Assay. The reactions oc-
curred in thesame conditions asdescribed aboveexceptthat the
inhibitor was added at seven different concentrations and DMSOArticle Journal of Medicinal Chemistry, 2010, Vol. 53, No. 19 6909
served as a control. The relative activity was set at 100% for
DMSO. The data were then fit to the eq 1:
y ¼ 100 expð-C=C0Þð 1Þ
The IC50 value is defined by -C0 ln(
1/2).
HomologyModeling.ThePP2CdomainsequenceofPHLPP2
(residues 745-1102) was used to make a homology model with
the program MODELER using the PP2C domain of PP2CR as
the reference structure.
19,20 The two sequences were aligned
using ClustalW. Next a model of PHLPP2 was created from
the reference structure using MODELER with default para-
meters. Further refinement of the model was performed by
placing varying amounts of Mn
2þ ions or water molecules in
the active site and then relaxing the structure with Macromodel
from the Schrodinger Suite.
49 The OPLS_2005 force field was
used with 500 iterations of the gradient method.
Similarity Searches and Compound Library Generation.
Accelrys software was used to search the NCI open repository,
using PHLPP2 inhibitors determined previously in this study as
reference compounds. Groups of inhibitors (families of com-
pounds, or top inhibitors) were submitted as the reference
compoundsusingthe“FindSimilarMoleculesbyFingerprints”
protocol provided with Accelrys Discovery Studio. Long range
functional class fingerprint description 6 keys (FCFP 6 keys)
were used with a Tanimoto distance coefficient to compute a
similarity score. Top scoring compounds were selected for
virtual screening.
Docking. The GLIDE virtual screening application in Schro-
dingerMolecularModelingSuitewasusedtoscreencompounds
usingthreelevelsofdockingprecision.Amodifiedversionofthe
Chemscore function is employed by GLIDE to assign a score to
each ligand in all poses. Glide HTVS was run on all compounds
to perform a complete conformational and positional search of
three-dimensional space in the active site. For the compounds
that scored in the highest 20%, GLIDE SP (standard precision)
was run. Similarly for the top 20% high scoring GLIDE SP
compounds, GLIDE XP (extra precision) was run too. Flexible
docking was allowed in all stages and default parameters from
theVirtualScreeningWorkflowwereusedinalldockingstudies,
in addition to the aforementioned modifications to the percent
of compounds entering each stage. All final scores and poses
came from GLIDE XP. The grids were generated for each
model in the phosphatase active site with the XYZ coordinates
(-27.54, 26.44, 46.38). An inner box which must contain the
center of each ligand docked was14 A ˚ in eachdirection, and the
outer box in which all parts of the ligand must bind was 44 A ˚ in
each direction. The relatively large box allowed for a variety of
docking poses and accepted large compounds. No other con-
straints were placed on the grids.
HomologyModelEvaluation.Dockingoftheinhibitorsfound
in the chemical screen into each modified homology model
helped determine the best model to use for further docking
studies. In addition, the experimentally validated binding com-
pounds with a G-score below -7 were considered to be virtual
hitsinthisstudy(Figure2c).Thedockingprotocolwasmodified
slightly in the evaluation of models so that all known inhibitors
were permitted to proceed through the three stages of GLIDE.
Also, the entire diversity set was docked into the models with
Mn
2þ in the active site, these studies were performed with only
the top 4% of compounds reaching the final GLIDE XP stage
and receiving scores as described in the docking protocol.
Models were evaluated based on the number of experimentally
confirmed inhibitors receiving a G-score of better than -7.
CellCultureandImmunoblotting.CellsaremaintainedinDMEM
supplemented with 5% FBS and 1% penicillin/streptomycin, at
37 Cin5%CO 2.Themediumwasaspiratedbeforeadditionoflysis
buffer (50 mM Tris pH 7.5, 1 mM sodium pyrophosphate, 20 mM
NaF, 2 mM EDTA, 1% Triton, 200 μM benzamidine, 40 μgm L
-1
leupeptin, 1 mM PMSF, and 1 μM microcystin). Whole cell lysates
wereanalyzedon7.5%SDS-PAGEgelsandWesternblottingusing
the indicated antibodies. Chemiluminescent signals were imaged by
an Alpha Innotech MultiImage III, and densitometric analysis was
performed using AlphaView software (version 2.0.0.9).
InhibitorTreatmentofCells.HT29cellswereplatedin12-well
plates and maintained in 5% FBS in DMEM. Four μL of the
different compounds diluted in DMSO were added to fresh
medium in each well. Cells were lysed in 200 μL of lysis buffer,
on ice, 24 h after addition of the inhibitors. For cellular IC50
studies, COS 7 cells were plated in 24-well plates. The cells were
starved for serum 24 h prior to the assay by placing them in
serum-freeDMEM.Theinhibitor(1or13)wasaddedatvarious
concentrations (4-400 or 3-300 μM, respectively) to each well,
and the cells were allowed to sit for 35 min in the incubator
before the plate was placed on ice. Cells were lysed in 100 μLo f
lysis buffer, and lysates were analyzed as described above.
DMSO was used as a control. The relative activity was set to 1
for DMSO. The data were then fit to eq 2.
y ¼ Að1-expð-C=C0ÞÞþ1 ð2Þ
For time course studies, COS 7 cells were plated in a 24-wells
plate. The cells were starved for serum 24 h prior to the assay by
placing them in serum-free DMEM. Cells were pretreated with
DMSO or 1 (50 μM) for 35 min. EGF was then added at
different time to a final concentration of 1 μgm L
-1. Between
thedifferenttimepoints,cellswereplacedbackintheincubator.
The control was obtained in the absence of EGF. The plate was
then placed on ice, and the cells were lysed in 100 μL of lysis
buffer.
Apoptosis Assay. COS 7 cells were plated in a 6-well plates.
When cellsreached80%confluency,mediumwasaspiratedand
replacedwith0.1%FBSinDMEM.DMSO,1,or13wereadded
to eachwellto ayielda finalconcentrationof50 μM.Following
30 min incubation at 37  C, DMSO or etoposide (50 μM) was
added. After 24 h, cells were detached from the plate using
trypsin, centrifuged at 100g for 5 min, 4  C, and stained with
Trypan Blue. Cells were manually counted, and the percentage
of dead cells was calculated.
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